BIB

ProShares Ultra Nasdaq Biotechnology · NAS

  • Category Health Care
  • Expense Ratio 0.95%
  • Listing Date Apr 08, 2010
  • Volume 7,001.0
  • Market Cap (AUM) $63.23M

Performance

-7.19%

1W

-3.94%

1M

-24.47%

3M

-8.73%

6M

-9.2%

YTD

+1.48%

1Y

Top Holdings

  • Name
    Symbol
    %Assets
  • United States Treasury Bills 0.0% 08-AUG-2024N/A17.83%
  • U.S. DollarN/A16.00%
  • Amgen Inc.AMGN6.05%
  • Vertex Pharmaceuticals IncorporatedVRTX6.02%
  • Regeneron Pharmaceuticals, Inc.REGN5.83%
  • Gilead Sciences, Inc.GILD4.75%
  • Moderna, Inc.MRNA3.52%
  • Astrazeneca PLC Sponsored ADRAZN3.16%
  • Biogen Inc.BIIB2.25%
  • Alnylam Pharmaceuticals, IncALNY1.34%

Technical Analysis of BIB 2024-12-20

The stock's indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the stock appears to be u...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.